IRIDEX Corporation (NASDAQ:IRIX) will release the third quarter earnings for 2009 on Thursday, November 12. The company will host a conference call at 5:00 pm ET that evening to discuss the financial results. Interested parties may access the call by dialing 888.561.1721 or 480.629.9868 for international callers. The conference ID will be 4181294. To hear a telephone replay of the call, dial 800.406.7325 or 303.590.3030 for international listeners. The access code for the replay will be 4181294. A webcast of the presentation will also be available online at http://www.iridex.com/.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
IRIDEX Corporation is a worldwide provider of therapeutic-based laser systems and delivery devices used to treat eye diseases in ophthalmology and skin conditions in dermatology (also referred to as aesthetics). The Company’s products are sold in the United States predominantly through a direct sales force and internationally through approximately 100 independent distributors into 107 countries. The Company operates in two segments: ophthalmology and aesthetics. The Company’s ophthalmology products consist of laser systems, delivery devices, and laser probes and are used in the treatment of eye diseases, including diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). Its aesthetics business focuses primarily on pigmented and vascular lesions, skin rejuvenation, skin tightening, hair reduction, leg veins, and acne.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
